 |
|
|
|
 |
|
|
| Article 1 to 10 out of 14 concerning Cambrex Corporation
|
-
Cambrex Completes Sale of Two Non-Strategic Human Health Facilities
(01 Nov 2006)
Cambrex Corporation announced that the sale of its Human Health facilities in Cork, Ireland, and Landen, Belgium, to International Chemical Investors S.A. II (ICIG) of Luxembourg had been completed on October 27, 2006."The completion of this ...
-
Cambrex Corporation and Cytori Therapeutics Enter Into Collaboration to Provide Adipose Derived Stem Cell Research Products
(16 Jun 2006)
Cambrex Bio Science Walkersville, Inc., a subsidiary of Cambrex Corporation, and Cytori Therapeutics announced that they have entered into a strategic marketing agreement to provide adipose-derived stem cell products globally for use in basic and ...
-
Cambrex Licenses Cell Line to Chugai Pharmaceutical Co.
(23 Feb 2006)
Cambrex Bio Science Walkersville, Inc., a subsidiary of Cambrex, announced that its client Chugai Pharmaceutical Co., Ltd. completed their assessment of certain of its Clonetics(R) Conditionally Immortalized Cell Lines under the previously announced ...
-
Geron and Cambrex Announce Contract Manufacturing Arrangement for cGMP Production of GRNVAC1 for Clinical Trials
(15 Feb 2006)
Geron Corporation and Cambrex Bio Science Walkersville, Inc., a subsidiary of Cambrex Corporation, announced an agreement for the manufacture of Geron's GRNVAC1 telomerase vaccine. The agreement provides for the transfer of Geron's vaccine ...
-
Cambrex Acquires Cutanogen Corporation
(07 Feb 2006)
Cambrex Bio Science Walkersville, Inc., a subsidiary of Cambrex Corporation, announced it has entered into a purchase agreement for all of the stock of Cutanogen Corporation, a privately-held biotechnology company that is focused on products used to ...
-
Cambrex Licenses Cell Lines to Chugai Pharmaceutical Co.
(05 Oct 2005)
Cambrex Bioscience Walkersville, Inc., a subsidiary of Cambrex Corporation, announced that they have signed an evaluation license agreement with Chugai Pharmaceutical Co., Ltd. for the use of certain Cambrex Clonetics® Conditionally Immortalized ...
-
David R. Bethune Joins the Cambrex Board of Directors
(08 Jun 2005)
Cambrex Corporation announced that David R. Bethune was elected to the Cambrex Board of Directors on June 2, 2005.David R. Bethune most recently was Chairman and Chief Executive Officer of Atrix Laboratories, a drug delivery and product development ...
-
New Gene Expression Data for Cambrex Primary Cells
(06 Jun 2005)
Cambrex Bio Science Walkersville, Inc., a subsidiary of Cambrex Corporation, announced the availability of gene expression data and summary analyses for several primary human cell types. A comparison of the gene expression patterns between the ...
-
Cambrex Licenses Powerful Technologies for Conditionally Immortalized Cells For Use in Drug Discovery
(21 Jan 2005)
Cambrex Corporation announced that its subsidiary Cambrex Bio Science Wokingham, Ltd. has signed an agreement for the purchase of conditionally immortalized cell lines, related intellectual property and equipment of Xcellsyz Limited, Newcastle Upon ...
-
DOR BioPharma and Cambrex Enter into a Development and Manufacturing Process Agreement for RiVax(TM)
(20 Jan 2005)
DOR BioPharma, Inc. and a subsidiary of Cambrex Corporation have entered into an agreement with respect to process development for potential large scale production of DOR's proprietary ricin vaccine, RiVax(TM). Under the agreement, Cambrex will ...
|
|
|
|
|
Top
